Association of tumor mutation burden and epidermal growth factor receptor inhibitor history with survival in patients with metastatic stage III/IV nonsmall-cell lung cancer: A retrospective study. (2021). Clinics, 76, e2251. https://doi.org/10.6061/clinics/2021/e2251